Aβ42 inhibits mTORC1 and treatment with IGF-1 alleviates the mTORC1 inhibition. (a) Representative Western blot and (b) densitometric analysis demonstrate that treatment of organotypic slices with Aβ42 for 72 hours significantly attenuates the phosphorylation of mTOR. IGF-1 treatment increases the phosphorylation of mTOR by 2 fold and reverses the reduction conferred by Aβ42 on mTOR phosphorylation. (c,d) Treatment of organotypic slices with Aβ42 significantly attenuates the phosphorylation of p70S6K1, the downstream substrate and indicator of mTORC1 activation. IGF-1 treatment increases phosphorylation of p70S6K1 by 1.7 fold and reverses the reduction induced by Aβ42 on p70S6K1 phosphorylation. *p < 0.05 and **p < 0.01 versus control; † † p < 0.01 and † † † p < 0.001 versus Aβ42.